Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
04 November 1993Website:
http://www.incyte.comNext earnings report:
01 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:09:49 GMTDividend
Analysts recommendations
Institutional Ownership
INCY Latest News
In recent months, Incyte's management has continued to delight investors by accelerating the pace of development of its anti-inflammatory treatments. On May 30, 2024, Incyte announced the completion of its acquisition of Escient Pharmaceuticals for $750 million. Sales of Opzelura, one of the company's gems, totaled $85.7 million in the first quarter of 2024, up 51.4% year-on-year.
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces Final Results of Tender Offer.
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces Preliminary Results of Tender Offer.
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Dublin, June 07, 2024 (GLOBE NEWSWIRE) -- The "Malignant Mesothelioma - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings.
Incyte (INCY) saw a 7% increase in its stock price over the course of a week, as investors reacted positively to the company's buyback initiative aimed at enhancing returns.
The stock price of Incyte Inc., a biopharmaceutical company, is currently trading at $58 per share, which is approximately 43% lower than its peak of $100 in January 2021. In early June 2022, INCY stock was valued at around $76, but has since dropped by 24% following the Fed's decision to raise rates. In comparison, the S&P 500 has experienced a significant 38% increase during this time.
The main U.S. stock market indexes showed little movement on Monday as the new trading week began, with a mix of gains and losses, and investors are expecting some important economic data later in the week.
What type of business is Incyte?
Incyte Corporation is a biopharmaceutical company. The company offers the drug JAKAFI for the treatment of myelofibrosis and polycythemia, as well as Iclusig, a kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Its clinical products include ruxolitinib, a Phase III drug for steroid-refractory chronic graft-versus-host disease (GVHD); and Phase II drug for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company is developing itacitinib, which is in Phase III clinical trials for the treatment of naïve chronic GVHD; and pemigatinib, which is in Phase II clinical trials for the treatment of bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and tumor-agnostic syndrome. The company is also involved in the development of Parsaclisib, which is in Phase II clinical trials for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. The company is developing INCMGA0012, which is in Phase II clinical trials for high-grade endometrial MSI cancer, Merkel
What sector is Incyte in?
Incyte is in the Healthcare sector
What industry is Incyte in?
Incyte is in the Biotechnology industry
What country is Incyte from?
Incyte is headquartered in United States
When did Incyte go public?
Incyte initial public offering (IPO) was on 04 November 1993
What is Incyte website?
https://www.incyte.com
Is Incyte in the S&P 500?
Yes, Incyte is included in the S&P 500 index
Is Incyte in the NASDAQ 100?
No, Incyte is not included in the NASDAQ 100 index
Is Incyte in the Dow Jones?
No, Incyte is not included in the Dow Jones index
When does Incyte report earnings?
The next expected earnings date for Incyte is 01 August 2024